Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Judith Karp

Showing results (21-30 of 23) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 23 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 28, 2010
NF1 inactivation in adult acute myelogenous leukemiaBrian Parkin, Peter Ouillette, Yin Wang, et al.
Leukemia Research|November 13, 2021
Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trialSelina M Luger, Victoria X Wang, Jacob M Rowe, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2006
Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemiaFrancis Giles, David Rizzieri, Judith Karp, et al.
Pageof 3

Showing results (21-30 of 23) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 23 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 28, 2010
NF1 inactivation in adult acute myelogenous leukemiaBrian Parkin, Peter Ouillette, Yin Wang, et al.
Leukemia Research|November 13, 2021
Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trialSelina M Luger, Victoria X Wang, Jacob M Rowe, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2006
Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemiaFrancis Giles, David Rizzieri, Judith Karp, et al.
Pageof 3